Litcius/Paper detail

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study

Thomas Yau, Ahmed O. Kaseb, Ann‐Lii Cheng, Shukui Qin, Andrew X. Zhu, Stephen L. Chan, Tamar Melkadze, Wattana Sukeepaisarnjaroen, Valery Breder, Gontran Verset, Edward Gane, Ivan Borbath, Jose David Gomez Rangel, Baek‐Yeol Ryoo, Tamta Makharadze, Philippe Merle, Fawzi Benzaghou, Steven Milwee, Zhong Wang, Dominic Curran, Robin Kate Kelley, Lorenza Rimassa

2024˜The œLancet. Gastroenterology & hepatology83 citationsDOIOpen Access PDF

Topics & Concepts

AtezolizumabSorafenibCabozantinibHepatocellular carcinomaMedicineOncologyInternal medicinePembrolizumabCancerImmunotherapyHepatocellular Carcinoma Treatment and PrognosisCholangiocarcinoma and Gallbladder Cancer StudiesLiver physiology and pathology